Immunogenicity of Bcl-2 in patients with cancer.

Blood
Mads Hald AndersenPer Thor Straten

Abstract

B-cell lymphoma 2 (Bcl-2) is a pivotal regulator of apoptotic cell death and it is overexpressed in many cancers. Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2-specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The overexpression of Bcl-2 in cancer and the fact that immune escape by down-regulation or loss of expression of this protein would impair sustained tumor growth makes Bcl-2 a very attractive target for anticancer immunotherapy. Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types (ie, pancreatic cancer, breast cancer, acute myeloid leukemia [AML], and chronic lymphocytic leukemia [CLL]). Additionally, we show that these Bcl-2-reactive T cells are indeed peptide-specific, cytotoxic effector cells. Thus, Bcl-2 may serve as an important and widely applicable target for anticancer ...Continue Reading

References

Jan 1, 1990·International Immunology·J K HicklingJ B Rothbard
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·H G WangJ C Reed
Dec 9, 1997·Cell·G S Salvesen, V M Dixit
Mar 31, 1998·Journal of Immunological Methods·M McCutcheonE G Spack
Dec 2, 1998·International Journal of Cancer. Journal International Du Cancer·S D'SouzaP Romero
Jan 23, 1999·Oncogene·J C Reed
Sep 17, 1999·Tissue Antigens·M H AndersenJ S Haurum
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·W HerrW J Storkus
Jun 16, 2000·Journal of Immunological Methods·F H RininslandM Tary-Lehmann
Feb 13, 2001·Biochemical and Biophysical Research Communications·S Y SunG S Wu
Apr 24, 2001·Cancer Immunology, Immunotherapy : CII·N RenkvistG Parmiani
May 5, 2001·Brain Research. Brain Research Reviews·M Bredel
Jun 8, 2001·International Journal of Cancer. Journal International Du Cancer·Z S ChenS Akiyama
Jul 18, 2001·Leukemia·M K White, J A McCubrey
Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·M GriffioenS Osanto
Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Carmen ScheibenbogenDirk Schadendorf
Jun 6, 2002·Journal of the National Cancer Institute·Giorgio ParmianiAndrea Anichini
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C M RudinE E Vokes
Oct 5, 2002·Cellular and Molecular Life Sciences : CMLS·N ZaffaroniM G Daidone
Oct 31, 2002·Seminars in Oncology·Jean-Pascal MachielsMarie Marchand
Dec 13, 2002·Vaccine·Michael CampoliSoldano Ferrone
Mar 26, 2003·Seminars in Cancer Biology·Leigh Coultas, Andreas Strasser
Apr 30, 2003·Current Treatment Options in Oncology·Aaron D SchimmerJohn C Reed
Sep 19, 2003·Cancer Immunology, Immunotherapy : CII·Panagiota A SotiropoulouConstantin N Baxevanis
Nov 25, 2003·Oncogene·Suzanne CoryJerry M Adams
Dec 31, 2003·Journal of Translational Medicine·Kimberly Shafer-WeaverAnatoli Malyguine
Jan 9, 2004·International Journal of Cancer. Journal International Du Cancer·Sine RekerMads Hald Andersen
Jan 17, 2004·Cancer Biology & Therapy·Sine RekerMads Hald Andersen
Feb 10, 2004·Laboratory Investigation; a Journal of Technical Methods and Pathology·Hongbin ZhaElaine S Jaffe
Mar 6, 2004·Seminars in Cancer Biology·Mads Hald AndersenPer thor Straten
Mar 11, 2004·The Journal of Investigative Dermatology·Mads Hald AndersenPer thor Straten

❮ Previous
Next ❯

Citations

Feb 2, 2006·Cancer Immunology, Immunotherapy : CII·Lucas ChanFarzin Farzaneh
Dec 21, 2006·Cancer Immunology, Immunotherapy : CII·Barbara-Ann GuinnKen I Mills
Feb 21, 2008·Cancer Immunology, Immunotherapy : CII·Mads Hald AndersenPer Thor Straten
Apr 17, 2008·Cancer Immunology, Immunotherapy : CII·Lynn WenandyMads Hald Andersen
Oct 2, 2008·Cancer Immunology, Immunotherapy : CII·Rikke Baek SørensenMads Hald Andersen
Aug 28, 2009·Cancer Immunology, Immunotherapy : CII·Nicola HardwickFarzin Farzaneh
Oct 29, 2010·Cancer Immunology, Immunotherapy : CII·Rikke Sick AndersenMads Hald Andersen
May 3, 2005·Nature Reviews. Drug Discovery·Mads Hald AndersenPer thor Straten
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Su-hu LiuWang-Gang Zhang
Jun 21, 2008·Molecular Cancer Therapeutics·Dayong ZhaiJohn C Reed
Sep 5, 2006·Journal of Translational Medicine·Mads Hald AndersenPer thor Straten
Feb 24, 2009·Journal of Cancer Research and Clinical Oncology·Carsten ZwickMichael Pfreundschuh
Aug 3, 2007·Expert Review of Vaccines·Martijn S BijkerSjoerd H van der Burg
May 17, 2006·The Journal of Investigative Dermatology·Martin Leverkus, Harald Gollnick
Dec 22, 2006·Cancer Letters·Mingjun WangMogens H Claësson
May 16, 2009·Cancer Science·Yoshihiko HirohashiNoriyuki Sato
Feb 21, 2008·European Journal of Haematology·Jochen Greiner, Michael Schmitt
Oct 8, 2008·Annals of the New York Academy of Sciences·Andalib AlirezaBabazadeh Shadi
Jan 15, 2013·American Journal of Reproductive Immunology : AJRI·Xuefeng WangXiafei Fu
Jul 10, 2010·Journal of Biomedicine & Biotechnology·Mads Hald AndersenPer Thor Straten
Sep 28, 2013·Oncoimmunology·Rikke Sick AndersenSine Reker Hadrup
Jan 1, 2014·Oncoimmunology·Stine Kiaer LarsenMads Hald Andersen
Jun 21, 2019·Viruses·Clemens Bretscher, Antonio Marchini
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jochen GreinerMichael Schmitt
Feb 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rikke Baek SørensenPer thor Straten

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.